A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).

被引：0
|
作者：
Schadendorf, Dirk
Ascierto, Paolo Antonio
Espinosa, Enrique
Haanen, John B. A. G.
Hermann, Frank
Nathan, Paul D.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Ist Nazl Tumori Fdn Pascale, Naples, Italy
[3] Univ Autonoma Madrid, Hosp Univ La Paz, Madrid, Spain
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] Bristol Myers Squibb, Munich, Germany
[6] Mt Vernon Canc Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9083
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
    Weber, Jeffrey S.
    Gibney, Geoff
    Sullivan, Ryan J.
    Sosman, Jeffrey A.
    Slingluff, Craig L., Jr.
    Lawrence, Donald P.
    Logan, Theodore F.
    Schuchter, Lynn M.
    Nair, Suresh
    Fecher, Leslie
    Buchbinder, Elizabeth I.
    Berghorn, Elmer
    Ruisi, Mary
    Kong, George
    Jiang, Joel
    Horak, Christine
    Hodi, F. Stephen
    LANCET ONCOLOGY, 2016, 17 (07): : 943 - 955
  • [32] Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.
    Zimmer, Lisa
    Eigentler, Thomas K.
    Vaubel, Julia-Marianne
    Mohr, Peter
    Jradi, Zeinab
    Kiecker, Felix
    Utikal, Jochen
    Berking, Carola
    Kaempgen, Eckhart
    Hauschild, Axel
    Dippel, Edgar
    Rompel, Rainer
    Fluck, Michael
    Stadler, Rudolf
    Herbst, Rudolf
    Terheyden, Patrick
    Garbe, Claus
    Loquai, Carmen
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
    O'Day, S. J.
    Maio, M.
    Chiarion-Sileni, V.
    Gajewski, T. F.
    Pehamberger, H.
    Bondarenko, I. N.
    Queirolo, P.
    Lundgren, L.
    Mikhailov, S.
    Roman, L.
    Verschraegen, C.
    Humphrey, R.
    Ibrahim, R.
    de Pril, V.
    Hoos, A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1712 - 1717
  • [34] Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
    Weber, Jeffrey S.
    D'Angelo, Sandra P.
    Minor, David
    Hodi, F. Stephen
    Gutzmer, Ralf
    Neyns, Bart
    Hoeller, Christoph
    Khushalani, Nikhil I.
    Miller, Wilson H., Jr.
    Lao, Christopher D.
    Linette, Gerald P.
    Thomas, Luc
    Lorigan, Paul
    Grossmann, Kenneth F.
    Hassel, Jessica C.
    Maio, Michele
    Sznol, Mario
    Ascierto, Paolo A.
    Mohr, Peter
    Chmielowski, Bartosz
    Bryce, Alan
    Svane, Inge M.
    Grob, Jean-Jacques
    Krackhardt, Angela M.
    Horak, Christine
    Lambert, Alexandre
    Yang, Arvin S.
    Larkin, James
    LANCET ONCOLOGY, 2015, 16 (04): : 375 - 384
  • [35] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
  • [36] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
    Lan, Chunyan
    Huang, Xin
    Shen, Jing-Xian
    Wang, Yin
    Xiong, Ying
    Li, Jundong
    Cao, Xinping
    Deng, Yanhong
    He, Mian
    Zou, Guorong
    Wang, Xiaodi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
    Cai, Z.
    Zhang, B.
    Yin, Y.
    Cao, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 698 - 698
  • [38] Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
    Wang, Xuan
    Wu, Xiaowen
    Yang, Yue
    Xu, Weiran
    Tian, Hui
    Lian, Bin
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Zhou, Li
    Mao, Lili
    Li, Siming
    Tang, Bixia
    Yan, Xieqiao
    Bai, Xue
    Guo, Jun
    Cui, ChuanLiang
    EUROPEAN JOURNAL OF CANCER, 2023, 182 : 57 - 65
  • [39] Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
    Wirth, Lori J.
    Brose, Marcia S.
    Sherman, Eric J.
    Licitra, Lisa
    Schlumberger, Martin
    Sherman, Steven, I
    Bible, Keith C.
    Robinson, Bruce
    Rodien, Patrice
    Godbert, Yann
    De La Fouchardiere, Christelle
    Newbold, Kate
    Nutting, Christopher
    Misir, Soamnauth
    Xie, Ran
    Almonte, Ana
    Ye, Weifei
    Cabanillas, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2359 - +
  • [40] Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
    Janjigian, Yelena Yuriy
    Adenis, Antoine
    Aucoin, Jean-Sebastien
    Barone, Carlo
    Boku, Narikazu
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345